36 results about "Estradiolum" patented technology

Drug eluting coating compositions are composed of at least one therapeutic agent dispersed in modified, biologically active binders. The therapeutic agents included in the coating composition are paclitaxel, sirolimus, tacrolimus, everolimus, actinomycin-D, dexamethasone, mycophenolic acid, cyclosporins, estradiol, and derivatives and analogs thereof. These therapeutic agents are applied to the surface of the medical device by a modified, biologically active binders. By using these biologically active binders, the therapeutic agents can be applied to at least one surface of a medical implant without using inert polymer carriers.

The instant invention discloses methods and compositions for the treatment of cancer. The invention relates methods and compositions for specifically targeting free radical accumulation as a means of preferentially eliminating neoplastic cells. The combination of an SOD inhibitor (2-methoxyestrdiol) with free radical-producing agents results in a means of eliminating tumor cells through the accumulation of intracellular superoxide anion.

The invention discloses a preparation method of a photoelectrochemical estradiol sensor, and belongs to the technical field of novel nano functional materials and biosensors. The method comprises the steps that a novel two-dimensional flaky magnetic photosensitive nanomaterial FeCo-N@TiO2 is prepared firstly, and by means of the good biocompatibility, large specific surface area and ferromagnetism of the material, the material is loaded with an estradiol antibody; alkaline phosphatase is fixed by means of the crosslinking action of glutaraldehyde; when detection is conducted, the alkaline phosphatase can catalyze sodium L-ascorbyl-2-phosphate (APP) to achieve in-situ generation of L-ascorbic acid (AA) to provide electron donors for photoelectric detection, the influence of specific quantitative combination of the antibody and an antigen on electron transmission capability is utilized for enabling the photoelectric current intensity to be correspondingly decreased, and the unmarked photoelectrochemical biosensor which is low in cost, high in sensitivity, good in specificity, rapid in detection and easy to prepare is finally prepared for detecting estradiol.

Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: wherein the variables are defined in the specification.

Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: wherein the variables are defined in the specification.

The invention provides a 17 beta estradiol-containing piperazine eutectic crystal as well as a preparation method and an application thereof. The X-ray powder diffraction analysis, thermogravimetic analysis, differential scanning calorimetry analysis and the like prove that the 17 beta estradiol-containing piperazine eutectic crystal provided by the invention has excellent physical chemistry property and medicine forming property. The preparation method of the eutectic crystal, provided by the invention, is simple to operate, easy to control and good in repeatability and can be used for obtaining the target eutectic crystal.

The invention relates to a novel cathode photoelectrochemical method for homogeneous phase detection of 17[Beta]-estradiol using a CuBi<2>O<4> material, and belongs to the field of analysis and detection. An ITO electrode modified by CuBi<2>O<4> is used as a working electrode, methylene blue (MB) or ferric chloride hemin that can be embedded in G-tetrahedra are used as photoelectrochemical signalmolecules, and the specific binding reaction between 17[Beta]-estradiol and aptamers is combined with the rolling circle amplification reaction (RCA) to control the insertion / release of the signal molecules, so that a homogeneous phase cathode photoelectrochemical detection method without biomolecule labeling and without fixing the biomolecules on the electrode surface is constructed. The novel cathode photoelectrochemical method for homogeneous phase detection of 17[Beta]-estradiol using the CuBi<2>O<4> material has high sensitivity and selectivity, with a linear range of 0.05 nmol / L - 10 nmol / L and a detection limit of 2.0 pmol / L.

The invention discloses a preparation method of a biological immunity sensor which is based on functional nano-material construction and has dual signal development strategies of electrogenerated chemiluminescence and photoelectrochemistry, and the prepared sensor is easy to operate, convenient to carry, fast in detection, low in cost and capable of being used for fast and sensitive detection of estradiol in the fields of routine production and life and the like.

Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula:wherein the variables are defined in the specification.

The invention discloses a culture medium and method for establishing pancreas or pancreatic cancer organoid and application, and the culture medium for establishing the pancreas or pancreatic cancer organoid can rapidly culture the pancreatic cancer organoid and form a 3D pancreatic cancer organoid which is highly consistent with pancreatic cancer tissue in genotype and morphology by blending components of the culture medium. The culture medium is a DMEM / F12 complete culture medium containing the following components: estradiol, hydrocortisone, R-Spondin 3, Neuregulin 1, FGF10, EGF (Epidermal Growth Factor), PGE2, Noggin, A83-01, Wnt3a, Y-27632, SB202190, B27, N-acetylcysteine, nicotinamide, GlutaMax, fetal calf serum and penicillin / streptomycin double antibodies, and the identification method comprises the combination of KRAS G12C gene copy number detection and morphological identification.

The present invention relates to marine medaka genes responding to the exposure of endocrine-disrupting chemicals, and a method for diagnosing an aquatic eco-system contamination using the marine medaka genes. Specifically, the method for diagnosing an aquatic eco-system contamination, according to the present invention, makes use of marine medaka genes of which the expression amount changes according to 17β-estradiol, or marine medaka genes of which the expression amount changes according to bisphenol A. Since it was verified that genes of marine medaka exposed to 17β-estradiol are changed or genes of marine medaka exposed to bisphenol A are changed, the present invention can be used in a useful manner for a microarray chip in which marine medaka genes responding to 17β-estradiol or marine medaka genes responding to bisphenol A are integrated, for a diagnosis using same, and for a method for diagnosing health or detecting stress of a marine eco-system by applying a kit having the microarray chip.

The invention discloses a ten-medicine Xiang Lu, a preparation method thereof and a ginsenoside content analysis method, and belongs to the technical field of traditional Chinese medicine formulas. The capsule gives full play to the values of the traditional Chinese medicines, has the effects of soothing liver-qi stagnation, softening hardness to dissipate stagnation and the like, the pharmacodynamic material basis of ginseng is ginsenoside which has an adjusting effect on the neuroendocrine function of the pituitary-gonad axis and can excite the pituitary to secrete gonadotropin, promote biosynthesis of DNA and protein synthesis related zymoprotein and increase the gonad activity. Through the two-way regulation effect on the pituitary-gonad axis, the positive and negative feedback functions of neuroendocrine are balanced so as to achieve the purpose of reducing estradiol which is abnormally increased, and mammary gland cell proliferation controlled by ovarian hormone is inhibited; andinternal components of traditional Chinese medicines are selected as internal standards in a quantitative analysis of multiple components by single marker, and the content of the to-be-detected components is calculated by measuring relative correction factors (RCF) between the internal standards and other to-be-detected components, so that the use amount of reference substances is reduced, and the cost is saved.

The invention discloses application of 2-methoxyestradiol (2ME2) in treatment of systemic lupus erythematosus. 2ME2 can be used as a therapeutic medicine for systemic lupus erythematosus or a component contained in the therapeutic medicines. The systemic lupus erythematosus includes cutaneous lupus, lupus nephritis, lupus encephalopathy and other systemic or / and organic lupus diseases. 2ME2 is given in a tail vein injection manner with a dosage of 0.75 mu M / kg each time, or is given in an intragastric manner with a dosage of 100mu M / kg each time. 2ME2 is used for treating B6.MRL-Fas(lpr) mice. When used for treating lupus erythematosus model mice (MRL-Fas(lpr) mice), 2ME2 has the beneficial effects of lowering the autoantibody level of lupus erythematosus, reducing syndromes of nephritis related to lupus, and relieving lupus syndromes.

The invention discloses a lactobacillus fermentum with an effect of relieving osteoporosis and an application thereof, belongs to the technical field of microorganisms and the technical field of medicine and provides a lactobacillus fermentum CCFM1126. The lactobacillus fermentum CCFM1126 can prevent and / or treat osteoporosis, and has the specific effects of improving uterine coefficients of ovariectomized rats, significantly increasing the bone density of the ovariectomized rats, significantly increasing the cortical volume of the ovariectomized rats, significantly reducing the content of tartrate-resistant acid phosphatase in serum of the ovariectomized rats, significantly reducing the content of a type I collagen cross-linked C-terminal telopeptide in the serum of the ovariectomized rats, significantly reducing the content of a tumor necrosis factor-alpha in the serum of the ovariectomized rats, reducing the content of interleukin-1beta in the serum of the ovariectomized rats and significantly improving the content of estradiol in the serum of the ovariectomized rats.

The invention provides an effective Bacillus sp. with strong endurance capacity and E2 degrading ability and the bacillus is conserved in the China Center for Type Culture Collection; the conservation address is Wuhan University, the postal code is 430072, the CCTCC NO is M 209150, and the conservation date is July 15, 2009. The Bacillus sp. E2-Y is selected from a wastewater treatment unit, is the dominant strain in the wastewater treatment system and can adapt to complicated actual conditions, thus having wide application prospects.

The invention discloses 2-methoxyestramustine and a derivative thereof. The structural formula of the 2-methoxyestramustine is shown as a formula 1-4. According to the 2-methoxyestramustine disclosedby the invention, 2-methoxyestradiol is used as a carrier, an alkylating agent (nitrogen mustard) is connected through carbamate to form a bifunctional drug molecular compound, the whole molecule is used as an anti-mitotic agent, and after carbamate is metabolized and hydrolyzed in vivo, 2-methoxyestradiol released by metabolite mediation can still continue to play an anti-tumor role. The derivative of the 2-methoxyestradiol can be used as the prodrug of the 2-methoxyestradiol. The invention also discloses a preparation method of the 2-methoxyestramustine and the derivative thereof, the preparation method can be used for preparing the 2-methoxyestramustine and the derivative thereof, and the yield is relatively high. The invention further discloses application of the 2-methoxyestramustineand the derivative thereof in a medicine for treating tumors or multiple myeloma.

The invention relates to a method for preparing fulvestrant and intermediates, particularly to a method for preparing a fulvestrant intermediate. According to the method, estradiol is used as a starting raw material, and is linked to a protecting group to obtain an intermediate 1; the benzyl site of the intermediate 1 is hydroxylated to obtain an intermediate 2; the intermediate 2 is oxidized to obtain an intermediate 3; the intermediate 3 and an intermediate 4 (1,9-dibromo nonane is subjected to iodination to obtain an intermediate 4, ie., 1,9-diiodononane) are subjected to a condensation reaction to obtain an intermediate 5 (a compound represented by a formula I); the intermediate 5 and an intermediate 7 (4,4,5,5,5-pentafluoropentanol and p-toluenesulfonyl chloride are condensed, and thecondensed product reacts with thiourea to obtain p-toluenesulfonic acid pentafluorothiourea salt) are subjected to a reaction to obtain an intermediate 8; the intermediate 8 is subjected to deprotection-reduction to obtain an intermediate 9; and the intermediate 9 is oxidized to obtain a target product. The method has the advantages of simple operation process, high yield of fulvestrant and highpurity of fulvestrant, and is suitable for industrial mass production.

The invention discloses an application of nattokinase to a medicine for treating osteoporosis. The nattokinase is prepared by fermenting a nattokinase strain; the nattokinase used as an active component is applied to the medicine for treating osteoporosis alone or in combination with other medicines. The nattokinase has very good effects of reducing the s-TRAP value, increasing the bone mineral content, increasing mineral density and increasing calcitonin (CT), bone gla protein (BGP) and estradiol (E2), and the nattokinase can be found to have the remarkable effect of improving osteoporosis.

The invention relates to an application of 2-methoxyestradiol in preparation of a medicine for treating psoriasis. The research finds that 2-methoxyestradiol has the characteristics of anti-proliferation, anti-inflammation and anti-angiogenesis, and accords with the pathogenesis link of psoriasis, so that the 2-methoxyestradiol is prepared into an external preparation, especially an ointment, and can be externally applied to treat psoriasis. An animal model and a cell model prove that the 2-ME has an exact curative effect on skin lesion of a psoriasis model mouse; in a psoriasis cell model, the cell proliferation and angiogenesis inhibition and anti-inflammatory effects of 2-ME are proved. Therefore, the invention proves that the 2-methoxyestradiol has the function of treating psoriasis, not only that, the 2-methoxyestradiol for external use is good in tolerance, safe and free of obvious toxic and side effects, but also the operation of preparing the ointment for external use by using the 2-ME is easier.

The invention discloses a preparation method of a humic acid modified Fe2O3 nanomaterial and an application thereof to the removal of estradiol in the technical field of environment functional material preparation. The method comprises the steps: dissolving Fe(NO3)3.9H2O into deionized water; then, adding a KOH solution and an NaHCO3 solution, carrying out a thermal insulation reaction, and then,separating a sediment; and next, mixing a solid with humic acid, regulating the pH, carrying out constant-temperature vibration, and then, carrying out centrifugal separation. The humic acid modifiedFe2O3 nanomaterial prepared by using the preparation method has relatively large specific surface area and is more in adsorption site and relatively strong in adsorption capacity due to various functional groups on the surface.

The invention discloses application of estradiol benzoate or a pharmaceutically acceptable salt thereof in preparation of anti-coronavirus drugs. The application of estradiol benzoate or the pharmaceutically acceptable salt thereof in preparation of the anti-coronavirus drugs is proposed for the first time, the application expands the application range of estradiol benzoate, and particularly, under the condition of epidemic global new coronal pneumonia, a new drug is provided for inhibiting new coronal pneumonia caused by SARS-CoV-2.

The invention provides a metabonomics method for preparing an animal model for treating primary dysmenorrhea based on modified inexhaustible tablets, the metabonomics method is a non-disease treatment purpose method, estradiol benzoate and oxytocin are combined to copy a primary dysmenorrhea rat model, the modified inexhaustible tablets are used for performing intervention treatment on the primary dysmenorrhea rat model, and the treatment effect is good. Acquiring metabolic map information of the treated rat serum sample based on a gas chromatography-time-of-flight mass spectrometer; data are processed and analyzed, biomarkers with significant difference are screened out, metabolic pathways in which the biomarkers participate are analyzed through a website, and the action mechanism of the modified inexhaustible tablets for treating primary dysmenorrhea is discussed. According to the method, the influence and change rule of external stimulation on endogenous micromolecules of organisms are researched from the overall perspective, a metabonomics method is matched with the overall view of traditional Chinese medicines, and a new research thought and method are provided for research on traditional Chinese medicine syndromes and the overall action mechanism of the traditional Chinese medicines.

The invention discloses prenatal test paper. A nitrocellulose membrane is arranged in the middle of a prenatal test paper bottom plate; an anti-estradiol (E2) monoclonal antibody detection line is arranged on the nitrocellulose membrane; a water absorption layer is arranged at one end of the bottom plate, a glass fiber sample layer is arranged at the other end of the bottom plate, the two ends ofthe nitrocellulose membrane are respectively connected with the water absorption layer and the glass fiber sample layer in an overlapping manner, a layer of anti-estradiol (E2) monoclonal antibody gold-labeled pad is clamped in the middle of the glass fiber sample layer, and the reaction value of a detection line is set to be greater than or equal to 50pg / ml. According to the prenatal test paper,the optimal prenatal opportunity can be finally obtained by confirming the ovulation day.

The invention discloses a method for determining an endocrine disrupter in a water body, the method comprises the following steps: (1) taking a water body to be detected, and adding an internal standard substance to obtain a mixed solution; (2) extracting, filtering and purifying the mixed solution to obtain a solution to be detected; and (3) measuring the solution to be measured by using a liquid chromatography tandem mass spectrometer to obtain the content of the endocrine disrupter in the solution to be measured, wherein the endocrine disrupter includes estrone, estradiol, bisphenol A, octyl phenol, nonyl phenol, triclosan and triclocarban. By implementing the method, the content of the endocrine disrupter in the water body can be accurately and efficiently measured, and a good data basis is provided for subsequent effective control of the content of the endocrine disrupter in the water body.

The invention discloses an estradiol production device. The device comprises a reaction kettle, an elutriation kettle, a centrifuge, a concentrating kettle, a decolorization kettle and a drying device, wherein the drying device comprises an outer cylinder, a drying cylinder and an inner cylinder, a motor is arranged on the bottom surface of the outer cylinder, and an exhaust fan blade, a cylinder-type impeller and a vortex impeller are arranged on the rotating shaft of the motor; the exhaust fan blade is disposed between the drying cylinder and the bottom surface of the outer cylinder, the cylinder-type impeller is disposed between the drying cylinder and the inner cylinder, and the vortex impeller is arranged at the bottom of the inner cylinder; an infrared heating tube is arranged on thetop surface of the inner cylinder, an air purifying ring is arranged at the upper end of a sandwich cavity of the outer cylinder, and a material inlet is formed in the center of a top plate; a sliding rod is arranged at the edge of the material inlet, a tray is connected to the lower end of the sliding rod, and a screw rod is arranged on the side edge of the material inlet; a screw sleeve is arranged on the screw rod, a gear ring which is arranged on the screw sleeve is meshed with a drive gear, and the drive gear is connected with a drive motor; and the lower end of the screw rod is connected with the tray, and a cover plate is connected with tops of the sliding rod and the screw rod. Through the estradiol production device, the preparation time of an intermediate product during production of estradiol can be reduced, and rapid high-quality production of estradiol can be realized.